TST001 + oxaliplatin + capecitabine

TST001 + oxaliplatin + capecitabine is a **three-drug combination regimen** for cancer therapy, specifically evaluated as first-line treatment in patients with **gastric cancer (G/GEJ)** and possibly other solid tumors. - **TST001** (osemitamab) is a recombinant humanized IgG1 monoclonal antibody targeting **Claudin 18.2 (CLDN18.2)**, a cell surface protein overexpressed in gastric, gastroesophageal junction, and other cancers. It is engineered for enhanced antibody-dependent cellular cytotoxicity (ADCC) and intended to kill CLDN18.2-positive tumor cells[1][3][5][7]. - **Oxaliplatin** is a platinum-based small molecule cytotoxic drug, acting by cross-linking DNA and causing apoptosis. - **Capecitabine** (Xeloda) is an oral prodrug of 5-fluorouracil (5-FU), a cytotoxic antimetabolite interfering with DNA synthesis[2][4][6]. The combination, often with abbreviated name **CAPOX** for capecitabine plus oxaliplatin, is well-tolerated, with common adverse effects including nausea, vomiting, hypoalbuminemia (primarily low grade), neutropenia, and thrombocytopenia. In the latest trials, the triple combination (with or without additional immune checkpoint inhibitors) shows promising safety and anti-tumor activity for advanced G/GEJ cancer, including in CLDN18.2-negative patients. It is under active development and has received orphan designation for these cancer indications[3][5].

Brand names

Osemitamab

Other names

CAPOX